


## Vebicorvir

Cat. No.:	HY-109195		
CAS No.:	2090064-66-5		
Molecular Formula:	C <sub>19</sub> H <sub>12</sub> F <sub>3</sub> N <sub>3</sub> O <sub>4</sub> S <sub>2</sub>		
Molecular Weight:	467.44		
Target:	HBV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (213.93 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1393 mL	10.6966 mL	21.3931 mL
		5 mM	0.4279 mL	2.1393 mL	4.2786 mL
10 mM		0.2139 mL	1.0697 mL	2.1393 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.45 mM); Suspended solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC <sub>50</sub> s from 1.84 μM to 7.3 μM <sup>[1]</sup> .
In Vitro	Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC <sub>50</sub> s of 2.68 μM, 4.95 μM, and 7.30 μM, respectively <sup>[1]</sup> . Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	After i.v. administration, the drug rapidly distributes and decays in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86 ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow,

---

in mouse, rat, dog, and monkey, respectively<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Anal Methods. 2021 Dec 17.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Qi Huang, et al. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA